MiCheck® Clinically Significant Prostate Cancer Risk Assessment
PSA alone isn't enough. MiCheck® Prostate uses validated biomarker testing to assess risk for clinically significant prostate cancer (csPCa), helping you and your patients make informed biopsy decisions or actively monitor. In-office testing with results that support confident clinical conversations.
Beyond PSA: Better Clinically Significant Prostate Cancer Risk Assessment
Elevated PSA creates a clinical dilemma. It may indicate clinically significant prostate cancer—or it may reflect benign conditions, inflammation, or low-grade disease that doesn’t require intervention. PSA alone can’t distinguish between these possibilities with the precision patients and clinicians need.
The result: unnecessary biopsies. Procedures with real risks and patient anxiety, performed on men who ultimately don’t have clinically significant disease. Or conversely, missed cancers in men whose PSA didn’t raise adequate concern.
MiCheck® Prostate addresses this gap. Validated biomarker testing goes beyond PSA to assess risk for clinically significant prostate cancer specifically—the disease that matters, the disease that requires intervention. Better risk stratification means better decisions: proceeding to biopsy when appropriate, avoiding it when the risk is low.
How MiCheck® Prostate Works
MiCheck Prostate® analyzes biomarkers associated with clinically significant prostate cancer to generate a risk assessment that goes beyond what PSA alone can provide. The test evaluates multiple indicators to distinguish elevated-risk patients from those whose findings are more likely benign or clinically insignificant.
Unlike send-out tests that require external laboratory processing and days of waiting, MiCheck® Prostate is designed for your physician office laboratory. Results are available to support clinical conversations with patients—facilitating shared decision-making about next steps, including whether biopsy is appropriate.
The goal isn’t just another number. It’s actionable risk assessment that helps you and your patient make confident decisions together.
Key Benefits
Superior csPCa Risk Assessment
Performance metrics designed to identify clinically significant prostate cancer—the disease that matters. Clinical studies have shown MiCheck® Prostate outperforms other available tests.
In-Office Testing
Run MiCheck® Prostate in your own POL, not as a send-out. Results available for same-visit or real-time clinical conversations.
Reduce Unnecessary Biopsies
Better risk stratification helps identify which patients truly need biopsy and which patients can be monitored—reducing procedures that wouldn't have changed management.
Beyond PSA Alone
Multi-biomarker approach provides clinical depth that single-marker PSA testing cannot match.
Support Shared Decision-Making
Give patients the information they need to participate meaningfully in decisions about their care.
Validated Performance
Biomarker testing backed by clinical validation for confident clinical use.
Sample Report
Sample MiCheck®Prostate report showing csPCa risk assessment. Clear presentation of risk level supports clinical decision-making and patient conversations.
Who Should Consider MiCheck Prostate
Urology Practices
Prostate cancer risk assessment is core to urological care. MiCheck Prostate brings validated biomarker testing in-house, improving the clinical conversation about biopsy decisions.
Patients with Elevated PSA
When PSA is elevated but clinical significance is uncertain, MiCheck Prostate provides additional risk stratification to guide next steps.
Biopsy Decision Support
For patients and clinicians weighing whether biopsy is appropriate, MiCheck Prostate offers objective risk assessment to inform the decision.
Practices Seeking PSA Alternatives
If you're looking for better tools than PSA alone to assess prostate cancer risk, MiCheck Prostate provides the multi-biomarker depth you need.
Common Questions
How is MiCheck ®Prostate different from PSA testing?
PSA is a single marker that can be elevated by many conditions besides clinically significant prostate cancer. MiCheck® Prostate uses multiple biomarkers to provide risk assessment specifically for csPCa—the disease that requires intervention.
Does MiCheck ®Prostate replace biopsy?
No. MiCheck P®rostate is a risk assessment tool to help determine whether biopsy is appropriate. It supports biopsy decision-making but doesn't replace the diagnostic role of biopsy itself.
Can I run MiCheck® Prostate in my POL?
Yes. MiCheck® Prostate is designed for physician office laboratories. Doc Lab provides implementation, training, and ongoing support.
How does MiCheck® Prostate compare to other prostate biomarker tests?
MiCheck® Prostate is designed to deliver superior performance metrics for csPCa risk assessment. We're happy to discuss comparative performance—contact us for details.
What patients should be tested with MiCheck® Prostate?
MiCheck® Prostate is appropriate for men being evaluated for possible prostate cancer—typically those with elevated PSA or other concerning findings where the question is whether to proceed to biopsy.